Prurigo excoriée treated with low dose naltrexone

2021 ◽  
Vol 14 (11) ◽  
pp. e243773
Author(s):  
Leonard Timoney ◽  
Christopher B Bunker
Keyword(s):  
Quality Of Life ◽  
Brain Tumour ◽  
Low Dose ◽  
Treatment Approach ◽  
Beneficial Impact ◽  
History Of ◽  
Modal Treatment ◽  
Low Dose Naltrexone ◽  
Systemic Agents

A 53-year-old woman presented with a 25-year history of acne excoriée and prurigo excoriée. Her symptoms began in 1988 coinciding with her husband’s death from a brain tumour when she was 27. The pruritus affected her quality of life and disturbed her sleep. She had scarring on her face and body resulting from persistent scratching. The pruritus proved refractory to treatment despite a multi-modal treatment approach including multiple topicals, phototherapy and systemic agents such as isotretinoin, antibiotics, anxiolytic agents and neuromodulators. She was extremely frustrated that various treatments had been ineffective at controlling the itch-scratch cycle. She was commenced on low dose naltrexone (LDN), 3 mg nocte, and she became itch free within a few weeks. She reports that the LDN has had a beneficial impact on her quality of life.

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis

2010 ◽  
pp. n/a-n/a ◽  
Author(s):  
Bruce A. C. Cree ◽  
Elena Kornyeyeva ◽  
Douglas S. Goodin
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Low Dose ◽  
Pilot Trial ◽  
Low Dose Naltrexone

Stuttering Impact: A Shared Perception for Parents and Children?

2019 ◽  
Vol 72 (6) ◽  
pp. 478-486 ◽  
Author(s):  
Mónica Rocha ◽  
J. Scott Yaruss ◽  
Joana R. Rato
Keyword(s):  
Quality Of Life ◽  
Treatment Approach ◽  
Individualized Treatment ◽  
Negative Attitudes ◽  
School Aged Children ◽  
European Portuguese ◽  
Parents And Children ◽  
History Of ◽  
The Impact

<b><i>Background/Aims:</i></b> Previous research has provided information about how school-aged children perceive their own stuttering; however, less is known about how stuttering is perceived by their parents. The ways that parents view their children’s stuttering could influence how the children themselves react to it. This study proceeds to assess how parents’ perceptions of the impact of stuttering relate to the perceptions of children. <b><i>Method:</i></b> Participants were 50 children who stutter aged 7–12 years (mean = 9.10; SD = 1.7) and their parents, recruited from different cities in Portugal. The European Portuguese version of the Overall Assessment of the Speaker’s Experience of Stuttering was administered to the children, and an adapted version of the tool was administered to their parents. <b><i>Results:</i></b> Both parents and children showed generally similar overall impact ratings, typically falling in the mild and moderate ranges. Differences were observed in families with a history of stuttering: for those families, a comparison of parents’ and children’s scores revealed, in some domains, that parents perceived the impact of stuttering to be greater than the children did, especially related with children’s reactions to stuttering and their quality of life. <b><i>Conclusion:</i></b> Knowledge about how parents perceive the impact of stuttering on their children is important because families can play a key role in helping children cope with stuttering. These findings highlight the benefits of using an individualized treatment approach for each child that focuses on their perceptions, as well as on those of the parents, in order to address negative attitudes toward children’s stuttering.

The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial

2010 ◽  
Vol 16 (8) ◽  
pp. 964-969 ◽  
Author(s):  
Naser Sharafaddinzadeh ◽  
Ali Moghtaderi ◽  
Davood Kashipazha ◽  
Nastaran Majdinasab ◽  
Bita Shalbafan
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Low Dose ◽  
Therapeutic Option ◽  
Controlled Trial ◽  
Well Being ◽  
Secondary Progressive ◽  
Relapsing Remitting ◽  
Low Dose Naltrexone

Background: Low-dose naltrexone (LDN) may promote psychological well-being as well as generalized health especially in autoimmune disorders. The objective of this study is to assess the effect of LDN on the Quality of Life (QoL) of patients with relapsing—remitting and secondary progressive multiple sclerosis (MS) using the scales and composite scores of the MSQoL-54 questionnaire. Methods: A 17-week randomized, double-blind, placebo-controlled, parallel-group, crossover-design clinical trial was conducted in two universities. A total of 96 adult patients aged between 15 and 65 years with relapsing—remitting (RR) or secondary progressive (SP) clinically definite MS with disease duration longer than 6 months enrolled into the study. The primary outcome of the study was comparison of the scores of physical and mental health by conducting independent t-test of the results obtained in the middle and at the end of study between the two groups. Results: Variables including presence of pain, energy, emotional well-being, social, cognitive, and sexual functions, role limitation due to physical and emotional problems, health distress, and overall QoL did not show any meaningful statistically difference between the two groups. Factor analysis revealed that health perception scores were statistically different between the groups before starting, in the middle, and at the end of the study. Conclusion: The study clearly illustrates that LDN is a relatively safe therapeutic option in RRMS and SPMS but its efficacy is under question and probably a long duration trial is needed in the future.

scholarly journals Effects of Low-Dose Naltrexone on Quality of Life in High-Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial

2021 ◽  
Author(s):  
Katherine B Peters ◽  
Mary L Affronti ◽  
Sarah Woodring ◽  
Eric Lipp ◽  
Patrick Healy ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Radiation Therapy ◽  
Functional Assessment ◽  
Low Dose ◽  
High Grade Glioma ◽  
Concurrent Chemotherapy ◽  
High Grade ◽  
Double Blind ◽  
Low Dose Naltrexone

Abstract Purpose: At diagnosis and throughout the disease course, patients with high-grade glioma (HGG) experience a diminished quality of life (QOL) and increased fatigue. Naltrexone, an orally semisynthetic opiate antagonist, is FDA-approved for the treatment of heroin/alcohol addiction, and low dose naltrexone (LDN) has been observed to improve QOL and lower fatigue in other neurological illnesses, such as multiple sclerosis. LDN is believed to function as a partial agonist and can lead to shifts in neurochemicals that reduce fatigue. Based on this, we sought to study whether LDN has an impact on QOL and fatigue in patients with HGG. Methods: In a placebo-controlled, double-blind study, we randomized 110 HGG patients to receive placebo (N=56) or LDN 4.5 mg orally at night (N=54). Subjects received LDN or placebo at day 1 of concurrent radiation and temozolomide therapy and continued for 16 weeks. Change from baseline in patient-reported outcomes of QOL (Functional Assessment of Cancer Therapy-Brain) and fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) was assessed. Results: Demographics were WHO grade IV (85%), male (56%), KPS 90-100 (51%), grossly resected (55%), and mean age of 56 years. QOL and fatigue changes between baseline and post concurrent chemotherapy and radiation therapy were not significantly different between patients receiving LDN or placebo. The adverse event profile for LDN and placebo were similar and attributed to concomitant use of temozolomide. Conclusions: While safe to administer, LDN has no effect on QOL and fatigue in HGG patients during concurrent chemotherapy and radiation therapy. United States National Library of Medicine Clinical Trials.gov NCT01303835, Date 2/25/2011

scholarly journals Quality of Life in Hematologic Cancer Patients: A Randomized Clinical Trial of Low Dose Naltrexone Versus Placebo

2008 ◽  
Vol 5 (7) ◽  
pp. 872-875 ◽  
Author(s):  
Mohammad Ali Seifrabiei ◽  
Mohammad Abbasi ◽  
Ali Montazeri ◽  
Fatemeh Shahnazari ◽  
Arash Pooya
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Low Dose ◽  
Hematologic Cancer ◽  
Low Dose Naltrexone

Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes

2019 ◽  
Vol 36 (10) ◽  
pp. 907-912 ◽  
Author(s):  
Diana Trofimovitch ◽  
Steven J. Baumrucker
Keyword(s):  
Quality Of Life ◽  
Pain Management ◽  
Adverse Effects ◽  
Palliative Medicine ◽  
Low Dose ◽  
Comfort Care ◽  
Off Label ◽  
Nonmalignant Pain ◽  
Low Dose Naltrexone

Pain can have a devastating effect on the quality of life of patients in palliative medicine. Thus far, majority of research has been centered on opioid-based pain management, with a limited empirical evidence for the use of nonopioid medications in palliative care. However, opioid and nonopioid medications such as nonsteroidal anti-inflammatory drugs have their limitations in the clinical use due to risk of adverse effects, therefore, there is a need for more research to be directed to finding an alternative approach to pain management in comfort care setting. The purpose of this article is to discuss a potential new drug that would adequately alleviate pain and enhance quality of life without significant risks of adverse effects that would limit its use. Naltrexone is a reversible competitive antagonist at μ-opioid and κ-opioid receptors, which when used at standard doses of 50 to 150 mg was initially intended for use in opioid and alcohol use disorders. However, it was discovered that its use in low doses follows alternate pharmacodynamic pathways with various effects. When used in doses of 1 to 5 mg it acts as a glial modulator with a neuroprotective effect via inhibition of microglial activation. It binds to Toll-like receptor 4 and acts as an antagonist, therefore inhibiting the downstream cellular signaling pathways that ultimately lead to pro-inflammatory cytokines, therefore reducing inflammatory response. Its other mode of action involves transient opioid receptor blockade ensuing from low-dose use which upregulates opioid signaling resulting in increased levels of endogenous opioid production, known as opioid rebound effect. Low dose naltrexone has gained popularity as an off-label treatment of several autoimmune diseases including multiple sclerosis and inflammatory bowel disease, as well as chronic pain disorders including fibromyalgia, complex regional pain syndrome, and diabetic neuropathy. Low-dose naltrexone (LDN) may also have utility in improving mood disorders and the potential to enhance the quality of life. This article will therefore propose the potential off-label use of LDN in management of nonmalignant pain in the palliative medicine setting.

Low-dose naltrexone for disease prevention and quality of life

2009 ◽  
Vol 72 (3) ◽  
pp. 333-337 ◽  
Author(s):  
Norman Brown ◽  
Jaak Panksepp
Keyword(s):  
Quality Of Life ◽  
Disease Prevention ◽  
Low Dose ◽  
Low Dose Naltrexone

Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence

2017 ◽  
Vol 31 (10) ◽  
pp. 1369-1373 ◽  
Author(s):  
Stefano Tamburin ◽  
Marco Faccini ◽  
Rebecca Casari ◽  
Angela Federico ◽  
Laura Morbioli ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Antiepileptic Drugs ◽  
Low Dose ◽  
Low Risk ◽  
High Dose ◽  
Safe Procedure ◽  
Subcutaneous Infusion ◽  
Benzodiazepine Dependence ◽  
History Of

High-dose benzodiazepine (BZD) dependence represents an emerging and under-reported addiction phenomenon and is associated with reduced quality of life. To date there are no guidelines for the treatment of high-dose BZD withdrawal. Low-dose slow flumazenil infusion was reported to be effective for high-dose BZD detoxification, but there is concern about the risk of convulsions during this treatment. We evaluated the occurrence of seizures in 450 consecutive high-dose BZD dependence patients admitted to our unit from April 2012 to April 2016 for detoxification with low-dose slow subcutaneous infusion of flumazenil associated with routine anticonvulsant prophylaxis. In our sample, 22 patients (4.9%) reported history of convulsions when previously attempting BZD withdrawal. Only four patients (0.9%) had seizures during ( n = 2) or immediately after ( n = 2) flumazenil infusion. The two patients with seizures during flumazenil infusion were poly-drug misusers. The most common antiepileptic drugs (AEDs) used for anticonvulsant prophylaxis were either valproate 1000 mg or levetiracetam 1000 mg. Our data indicate that, when routinely associated with AEDs prophylaxis, low-dose slow subcutaneous flumazenil infusion represents a safe procedure, with low risk of seizure occurrence.

Sign in / Sign up

Export Citation Format

Share Document